Fairpointe Capital’s Novartis NVS Stock Holding History

Fairpointe Capital’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-2,300	Closed	-$200K	–	77
2020 Q3	$200K	Buy	+2,300	New	+$199K	0.03%	75
2014 Q1	–	Sell	-3,571	Closed	-$257K	–	80
2013 Q4	$257K	Hold	3,571	–	–	﹤0.01%	74
2013 Q3	$245K	Sell	3,571 -391	-10%	-$25.9K	﹤0.01%	74
2013 Q2	$251K	Buy	+3,962	New	+$258K	0.01%	69

Other funds holding NVS

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Aristotle Capital Management Los Angeles, California $47.8B AUM 13.38% 1-Year Est. Return

Mawer Investment Management Calgary, Alberta, Canada $15.4B AUM 10.9% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Fairpointe Capital's NVS Position: Q4 2020 in Review

Fairpointe Capital sold out of Novartis (NVS) in Q4 2020, closing a stake of 2,300 shares — an estimated $200K sold.

Fairpointe Capital first reported a position in NVS in Q2 2013 and held it in 4 quarters. The position peaked at $257K in Q4 2013. 1,177 funds tracked by Wall St. Rank hold NVS as of Q4 2020.

Fairpointe Capital reported no remaining Novartis position as of Q4 2020 after selling out during the quarter.
Fairpointe Capital sold 2,300 Novartis shares in Q4 2020, an estimated $200K.
Fairpointe Capital first reported a position in Novartis in Q2 2013 and held it in 4 quarters.
Fairpointe Capital's Novartis position peaked at $257K in Q4 2013.
1,177 funds tracked by Wall St. Rank held Novartis as of Q4 2020.

Based on Fairpointe Capital's 13F filing for Q4 2020, filed 11 Feb 2021.